Vaginal Estradiol vs Moisturizer for Menopause in Women with HIV

This trial explores how two treatments, vaginal estradiol and a vaginal moisturizer, affect menopause symptoms in women with HIV. It seeks to determine the impact of these treatments on vaginal and urinary symptoms, such as dryness, irritation, and frequent urinary tract infections. Women with HIV will be randomly assigned to either the estradiol or moisturizer group, while women without HIV will receive estradiol. Eligible participants include women with HIV who have experienced menopause symptoms like vaginal dryness or frequent UTIs within the last two years. As a Phase 4 trial, this research focuses on understanding how these FDA-approved treatments can benefit more patients.

The trial requires that you stop using certain medications before participating. You must not have used systemic reproductive hormones in the last 2 months, antibiotics in the last 30 days, immunosuppressive medications in the last 60 days, or any vaginal or vulvar preparations in the last month.

Previous studies have shown that vaginal estradiol is safe and effective for treating menopause symptoms in women without HIV. The FDA has approved it for this use, indicating strong evidence of its safety. Research shows that vaginal estradiol alleviates symptoms like dryness and irritation and might positively affect the vaginal microbiome.

Studies indicate that vaginal moisturizers effectively relieve discomfort and pain during sex for women with mild to moderate vaginal dryness. They are generally considered safe and often recommended as the first treatment option for menopause-related vaginal symptoms.

Researchers are excited about using vaginal estradiol and vaginal moisturizers to help women with HIV manage menopause symptoms. Unlike typical treatments that focus on hormone therapy like systemic estrogen, vaginal estradiol offers localized relief, potentially reducing systemic side effects while directly targeting symptoms like dryness. Vaginal moisturizers, on the other hand, provide a non-hormonal option, which can be appealing for those who prefer or need alternatives to hormone-based treatments. This trial aims to discover how these treatments might improve vaginal health and comfort specifically for women living with HIV, a group that often experiences unique challenges due to their condition.

This trial will compare the effectiveness of vaginal estradiol and vaginal moisturizer in women with HIV experiencing menopause-related symptoms. Studies have shown that vaginal estradiol effectively and safely treats symptoms such as vaginal dryness, irritation, and pain during sex in menopausal women without HIV, and the FDA has approved it for these symptoms. Participants in this trial may receive vaginal estradiol, which has more robust research supporting its use in menopausal women without HIV. Alternatively, participants may receive a vaginal moisturizer, like Replens, which can help with mild to moderate vaginal dryness and discomfort, although evidence for its long-term effectiveness is less strong.¹²³⁵⁶